↓ Skip to main content

Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities

Overview of attention for article published in Clinical Epigenetics, April 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
6 tweeters
patent
2 patents

Citations

dimensions_citation
98 Dimensions

Readers on

mendeley
112 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Published in
Clinical Epigenetics, April 2017
DOI 10.1186/s13148-017-0332-8
Pubmed ID
Authors

Goran Micevic, Nicholas Theodosakis, Marcus Bosenberg

Abstract

Aberrant DNA methylation is an epigenetic hallmark of melanoma, known to play important roles in melanoma formation and progression. Recent advances in genome-wide methylation methods have provided the means to identify differentially methylated genes, methylation signatures, and potential biomarkers. However, despite considerable effort and advances in cataloging methylation changes in melanoma, many questions remain unanswered. The aim of this review is to summarize recent developments, emerging trends, and important unresolved questions in the field of aberrant DNA methylation in melanoma. In addition to reviewing recent developments, we carefully synthesize the findings in an effort to provide a framework for understanding the current state and direction of the field. To facilitate clarity, we divided the review into DNA methylation changes in melanoma, biomarker opportunities, and therapeutic developments. We hope this review contributes to accelerating the utilization of the diagnostic, prognostic, and therapeutic potential of DNA methylation for the benefit of melanoma patients.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 <1%
Unknown 111 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 23 21%
Researcher 17 15%
Student > Master 15 13%
Student > Bachelor 12 11%
Other 8 7%
Other 18 16%
Unknown 19 17%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 34 30%
Medicine and Dentistry 26 23%
Agricultural and Biological Sciences 13 12%
Veterinary Science and Veterinary Medicine 3 3%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Other 11 10%
Unknown 22 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2019.
All research outputs
#1,324,796
of 20,281,428 outputs
Outputs from Clinical Epigenetics
#70
of 1,105 outputs
Outputs of similar age
#29,762
of 280,628 outputs
Outputs of similar age from Clinical Epigenetics
#1
of 6 outputs
Altmetric has tracked 20,281,428 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,105 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done particularly well, scoring higher than 93% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,628 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them